Search Articles — Sudonull

Search Results

From the web

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...

https://www.erasca.com/news/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-china-hong-kong-and-macau/

Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular ...

https://www.erasca.com/news/erasca-announces-issuance-of-a-u-s-patent-covering-pan-ras-molecular-glue-eras-0015/

Nov 6, 2025 · The patent claims protect the composition of matter for Erasca’s potentially best-in-class pan-RAS molecular glue ERAS-0015 and related compositions until September 2043, which may be …

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...

https://www.biospace.com/press-releases/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-china-hong-kong-and-macau

Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …

Erasca Announces Positive Preliminary Phase 1 Dose ... - BioSpace

https://www.biospace.com/press-releases/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors

Apr 28, 2026 · ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the …

Revolution Medicines Sues Erasca Over RAS Patent

https://allsci.com/news/patents-ip/revolution-medicines-asserts-patent-infringement-against-erascas-pan-ras-molecular-glue-eras-0015/

Apr 27, 2026 · Erasca, Inc. (USA) announced on April 27, 2026, via a US Securities and Exchange Commission Form 8-K filing, that Revolution Medicines, Inc. (RevMed, USA) had transmitted a letter …

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular ...

https://investingnews.com/erasca-announces-issuance-of-a-u-s-patent-covering-pan-ras-molecular-glue-eras-0015/

Nov 6, 2025 · Erasca is evaluating ERAS -0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. ERAS -4001 is an oral, highly potent, and selective pan-KRAS inhibitor with a...

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data …

https://investingnews.com/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors/

Apr 27, 2026 · ERAS -0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS...

Erasca secures worldwide rights to ERAS-0015 pan-RAS drug | ERAS …

https://www.stocktitan.net/news/ERAS/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-thx2dseut02z.html

Mar 10, 2026 · Erasca (Nasdaq: ERAS) exercised its option to expand the ERAS-0015 license with Joyo to include China, Hong Kong, and Macau, securing worldwide rights for the pan-RAS molecular glue.

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...

https://www.marketscreener.com/news/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-c-ce7e5fded08ff427

Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...

https://finviz.com/news/334880/erasca-exercises-option-to-secure-worldwide-rights-for-eras-0015-pan-ras-molecular-glue-to-include-china-hong-kong-and-macau

Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …

Trending Now